PartnerFacts
Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 6:55 AM ET

Sponsor Check › Person

JM
No photo found yet (own website and image search run after this page is viewed)

Joel S. Marcus

Named as an officer, director or promoter on SEC Form D filings · CA, NY, WA · Aug 11, 2009 → Jan 15, 2026

18deals (issuers)
$407Mreported sold
788investors
91Form D filings
2009–2026years on file
Follow this personLook further ↓PDF

Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:19 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET

The short version

Joel S. Marcus is listed as an executive officer and director on 91 SEC Form D filings by 18 issuers between Aug 2009 and Jan 2026. Largest by amount reported sold: Applied Therapeutics, Inc. (New York, NY — biotechnology — 2018–2024; $100M reported sold to 37 investors), INTRA CELLULAR THERAPIES INC (New York, NY — biotechnology — 2010–2013; $60M reported sold to 185 investors), AltPep Corp (Seattle, WA — biotechnology — 2022; $44.4M reported sold to 26 investors), TRex Holdings Inc. (South San Francisco, CA — biotechnology — 2024; $42.3M reported sold to 13 investors), Petra Pharma Corp (New York, NY — biotechnology — 2016–2018; $31.2M reported sold to 13 investors) and 13 more (all listed below).

What this means That is a lot of deals — 18 separate companies raised money with this person listed as executive officer and director, over about 17 years. Across those companies the filings report $407M sold in total.

Listed alongside Richard H. Klein (54 shared filings), Dean A. Shigenaga (51 shared filings), James Richardson (44 shared filings), John L. Atkins, III (44 shared filings), Richard B. Jennings (34 shared filings) and 122 others.

What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Joel. Each name links to their own page.

The issuers belong to 3 sponsor groups: Are (6 issuers, $1.62M reported sold, 2009–2026), Santa (3 issuers, $13.5M reported sold, 2013–2014) and Intra Cellular Therapies (2 issuers, $130.3M reported sold, 2010–2013).

What this means This person is listed across more than one sponsor team; each group page shows that team's full track record.

Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, LA, ME, MO, MS, MT, NASAA, NC, NH, NM, OR, RI, TX, WA) — 1 bankruptcy case matching the name listed in Key records below.

What this means 1 record came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.

We compared the newest 50 of 91 public filings for Joel S. Marcus and found 13 differences, 5 worth asking the sponsor about: 5 regulator actions name the subject or team members; Investor count went down between filings; and more below.

What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.

What the community is saying

Community search for Joel S. Marcus has not run yet — it is joining a line of 21,754 names; searches run around the clock at the hosts' allowed rate. Searched so far: 363 names.

Community comments are quoted as written by their authors. Sources searched: BiggerPockets forums (via DuckDuckGo, Brave, Bing and BiggerPockets search) and Reddit (search feed + public archive).

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:19 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: NV (crawled Oct 23, 2026)

What was searched

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched Joel S. Marcus..

State securities regulators: Securities regulators searched (3,318 actions): AZ Corporation Commission Securities Division (411 actions, 2017–2026), CA DFPI (25 actions, 2007–2024; listing starts 2002), DE DOJ Investor Protection Unit (257 actions, 1987–2026), TX State Securities Board (586 actions, 2006–2026), WA DFI (2,039 actions, 2001–2026) — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first — last crawled Oct 23, 2026, 9:57 PM ET. No machine-readable public listing today for IA, IN, KS, MI, NE, NV (see docs/state-regulators.md).

3. Bankruptcies

1 case: 1 closed (disposition not in docket feed)

Joel Marcus closed
United States Bankruptcy Court, D. New Jersey · No. 05-33639 · Filed Jul 21, 2005 · Closed Nov 9, 2005
Role of Joel Marcus: Debtor · Outcome: Case closed 2005-11-09 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (rare in federal dockets); 3 people with this name in Form D filings; court in NJ (not a filing state)
What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:19 AM ET.

Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

4. Differences between public sources

Comparisons cover issuers and sponsor groups — see the issuer pages under Deals

13 differences found between the filings for Joel S. Marcus — 5 worth asking about (compared the newest 50 of 91 filings on Oct 24, 2026; older filings not covered)

Worth asking · Jun 12, 2002 – Feb 1, 2018

5 regulator actions name the subject or team members

Regulator action naming a team member: Thomas Edward Andrews (Feb 1, 2018) · Regulator action naming a team member: Samuel D. Waksal and Jack Waksal, Defendants, and Patti Waksal, Relief Defendant (Jan 19, 2005) · Regulator action naming a team member: Samuel D. Waksal and Jack Waksal; Relief Defendant Patti Waksal (Oct 10, 2003) · Regulator action naming a team member: Samuel D. Waksal (Mar 11, 2003) · Regulator action naming a team member: Samuel D. Waksal (Jun 12, 2002)

What this means A regulator filed or announced an action naming this person or company (or someone on the same filings). Read the release; ask the sponsor what it was and how it ended.

Thomas Edward Andrews ↗Thomas J. Andrews — PartnerFacts page ↗Samuel D. Waksal and Jack Waksal, Defendants, and Patti Waksal, Relief Defendant ↗Samuel D Waksal — PartnerFacts page ↗
Sources
Note · Dec 29, 2023

Bankruptcy case: Equilibre Biopharmaceuticals Corp. — filed Dec 29, 2023

United States Bankruptcy Court, S.D. New York docket "Equilibre Biopharmaceuticals Corp." filed Dec 29, 2023 (Open). Equilibre BioPharmaceuticals Corp. (related issuer) is listed as Debtor ("Equilibre Biopharmaceuticals Corp."). Our match estimate: 80%.

What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.

Docket · United States Bankruptcy Court, S.D. New York ↗Equilibre BioPharmaceuticals Corp. — PartnerFacts page ↗
Sources
Worth asking · Jan 6, 2016 – Jan 4, 2017

Investor count went down between filings — Petra Pharma Corp

The Jan 6, 2016 filing reports 12 investors; the Jan 4, 2017 Form D/A reports 11 investors.

What this means Investor counts normally only grow. A smaller number can mean investors left or were refunded, or a count was corrected. Ask the sponsor what happened.

Form D (earlier) · Jan 6, 2016 ↗Form D/A (later) · Jan 4, 2017 ↗Petra Pharma Corp — PartnerFacts page ↗
Sources
Worth asking · Jan 16, 2015 – Jan 15, 2026

22 filings report more than 10% of the money raised going to insiders

117% of the money raised went to insiders — ALEXANDRIA REAL ESTATE EQUITIES, INC. · 6020% of the money raised went to insiders — ALEXANDRIA REAL ESTATE EQUITIES, INC. · 128% of the money raised went to insiders — ALEXANDRIA REAL ESTATE EQUITIES, INC. · 5047% of the money raised went to insiders — ALEXANDRIA REAL ESTATE EQUITIES, INC. · 128% of the money raised went to insiders — ALEXANDRIA REAL ESTATE EQUITIES, INC. · and 17 more

What this means The filing reports how much of the money raised was paid to insiders. Over 10% is high for most deals. Ask what it paid for.

Form D · Jan 15, 2026 ↗ALEXANDRIA REAL ESTATE EQUITIES, INC. — PartnerFacts page ↗Form D · Jan 15, 2026 ↗Form D · Jan 15, 2025 ↗
Sources
Worth asking · Jan 1, 2014 – Nov 26, 2024

8 Form Ds were filed more than 15 days after the first sale

Form D filed 380 days after the first sale — ALEXANDRIA REAL ESTATE EQUITIES, INC. · Form D filed 19 days after the first sale — TRex Holdings Inc. · Form D filed 16 days after the first sale — ALEXANDRIA REAL ESTATE EQUITIES, INC. · Form D filed 16 days after the first sale — ALEXANDRIA REAL ESTATE EQUITIES, INC. · Form D filed 17 days after the first sale — ALEXANDRIA REAL ESTATE EQUITIES, INC. · and 3 more

What this means Late notices are common and carry no penalty by themselves. A pattern of late paperwork is worth asking the sponsor about.

Form D · Jan 16, 2015 ↗ALEXANDRIA REAL ESTATE EQUITIES, INC. — PartnerFacts page ↗Form D · Nov 26, 2024 ↗TRex Holdings Inc. — PartnerFacts page ↗
Sources
Note · Jan 1, 2014 – Jan 15, 2025

30 offerings have no amendment in the last 12 months and may still be open

No amendment in the last 12 months on an offering that may still be open — ALEXANDRIA REAL ESTATE EQUITIES, INC. (latest filing Jan 15, 2025) · No amendment in the last 12 months on an offering that may still be open — ALEXANDRIA REAL ESTATE EQUITIES, INC. (latest filing Jan 15, 2025) · No amendment in the last 12 months on an offering that may still be open — TRex Holdings Inc. (latest filing Nov 26, 2024) · No amendment in the last 12 months on an offering that may still be open — ALEXANDRIA REAL ESTATE EQUITIES, INC. (latest filing Jan 16, 2024) · No amendment in the last 12 months on an offering that may still be open — ALEXANDRIA REAL ESTATE EQUITIES, INC. (latest filing Jan 16, 2024) · and 25 more

What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.

Form D · Jan 15, 2025 ↗ALEXANDRIA REAL ESTATE EQUITIES, INC. — PartnerFacts page ↗Form D · Jan 15, 2025 ↗Form D · Nov 26, 2024 ↗
Sources
Worth asking · Mar 29, 2019 – Apr 2, 2020

Joel S. Marcus is no longer listed on the Apr 2, 2020 amendment — Rodeo Therapeutics Corp

Joel S. Marcus appears on the Mar 29, 2019 Form D/A (director) but not on the Apr 2, 2020 Form D/A for the same offering.

What this means People leave, and the issuer must list only current officers, directors and promoters. It is still worth asking why this person left and who replaced them.

Form D/A · Mar 29, 2019 ↗Form D/A · Apr 2, 2020 ↗Joel S. Marcus — PartnerFacts page ↗Rodeo Therapeutics Corp — PartnerFacts page ↗
Sources
Note · Jan 4, 2016 – Apr 2, 2020

6 offerings changed their target amount between filings

Offering amount changed between filings — Rodeo Therapeutics Corp · Offering amount changed between filings — Proniras Corp · Offering amount changed between filings — Rodeo Therapeutics Corp · Offering amount changed between filings — ApoGen Biotechnologies, Inc. · Offering amount changed between filings — Petra Pharma Corp · and 1 more

What this means Targets change as deals grow or shrink. Ask whether later money has the same terms.

Form D/A (earlier) · Mar 29, 2019 ↗Form D/A (later) · Apr 2, 2020 ↗Rodeo Therapeutics Corp — PartnerFacts page ↗Form D (earlier) · Sep 5, 2017 ↗
Sources
Note · Jan 16, 2015 – Jan 4, 2016

Joel S. Marcus is written 2 different ways on the filings

listed as "Joel S. Marcus" on 28 filings (from Jan 16, 2015), and "Joel Marcus" on 22 filings (from Jan 4, 2016).

What this means Same person, written differently — a middle name or suffix left off, or spelled another way. It is normal, but check that the full legal name matches your subscription documents.

Form D · Jan 16, 2015 ↗Form D · Jan 4, 2016 ↗Joel S. Marcus — PartnerFacts page ↗
Sources
Note · Feb 20, 2018 – Nov 19, 2018

Industry group changed between filings — Applied Therapeutics, Inc.

"Other Health Care" (Feb 20, 2018); then "Biotechnology" (Nov 19, 2018 to Mar 13, 2024).

What this means The issuer described its business differently on different forms. Often it is just a different box ticked; sometimes the deal itself changed. Ask which business your money is in.

Form D · Feb 20, 2018 ↗Form D · Nov 19, 2018 ↗Applied Therapeutics, Inc. — PartnerFacts page ↗
Sources
Note · Mar 22, 2017 – May 15, 2020

Same name, different state: "Joel Marcus" (NC) is a separate record

This page covers filings where the address state is CA or NY or WA. A separate record, "Joel Marcus" with address state NC, is listed on 5 filings — most recently by Reactive Biosciences Inc. (May 15, 2020). Both records have filings in the same period (Mar 22, 2017 to May 15, 2020).

What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.

Joel Marcus (NC) — PartnerFacts page ↗Form D/A · May 15, 2020 ↗Reactive Biosciences Inc. — PartnerFacts page ↗Joel S. Marcus (CA,NY,WA) — this page ↗
Sources
Note · Feb 22, 2016 – Jul 23, 2019

Same name, different state: "Joel Marcus" (MA) is a separate record

This page covers filings where the address state is CA or NY or WA. A separate record, "Joel Marcus" with address state MA, is listed on 5 filings — most recently by Frequency Therapeutics, Inc. (Jul 27, 2020). Both records have filings in the same period (Feb 22, 2016 to Jul 23, 2019).

What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.

Joel Marcus (MA) — PartnerFacts page ↗Form D · Jul 27, 2020 ↗Frequency Therapeutics, Inc. — PartnerFacts page ↗Joel S. Marcus (CA,NY,WA) — this page ↗
Sources
Note · Jan 16, 2015 – Jan 15, 2026

Joel S. Marcus is listed with 3 different address states: CA, NY, WA

CA on 30 filings (Jan 16, 2015 to Jan 15, 2026); NY on 13 filings (Jan 4, 2016 to Mar 13, 2024); WA on 7 filings (Aug 2, 2017 to Jul 26, 2022).

What this means The address on a Form D is usually the company's, not the person's home, so this often just reflects different companies. It can also mean a move. Nothing wrong by itself.

Form D · Jan 16, 2015 ↗Form D · Jan 4, 2016 ↗Form D · Aug 2, 2017 ↗
Sources
What is compared

What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. We compared the newest 50 of 91 filings (work cap); older filings are not covered here. As of Oct 24, 2026.

5. Money to insiders

9 of 62 offerings report sales commissions totalling $14,715,762; 0 report finder's fees; 26 report proceeds to related persons totalling $42,899,803. (includes amounts the issuer reported as estimates)

Offering (latest filing)Sales commissionsFinder's feesTo insidersPaid to sell itSource
Jan 15, 2026 D
ALEXANDRIA REAL ESTATE EQUITIES, INC.
File 021-570154
$0$0$3,217,506 (est.)
Held by Issuer for payments of deferred compensation obligations to participants.
None listed on this filingEDGAR ↗
Jan 15, 2026 D
ALEXANDRIA REAL ESTATE EQUITIES, INC.
File 021-570156
$0$0$1,170,000
Held by Issuer for payments of deferred compensation obligations to participants.
None listed on this filingEDGAR ↗
Jan 15, 2025 D
ALEXANDRIA REAL ESTATE EQUITIES, INC.
File 021-535368
$0$0$3,338,283 (est.)
Held by Issuer for payments of deferred compensation obligations to participants.
None listed on this filingEDGAR ↗
Jan 15, 2025 D
ALEXANDRIA REAL ESTATE EQUITIES, INC.
File 021-535369
$0$0$1,280,000
Held by Issuer for payments of deferred compensation obligations to participants.
None listed on this filingEDGAR ↗
Nov 26, 2024 D
TRex Holdings Inc.
File 021-530561
$0$0$0None listed on this filingEDGAR ↗
Mar 13, 2024 D
Applied Therapeutics, Inc.
File 021-507505
$7,499,850 (est.)$0$0UBS Securities LLC BrokerCheck CRD 7654 ↗
Leerink Partners LLC BrokerCheck CRD 39011 ↗
RBC Capital Markets, LLC BrokerCheck CRD 31194 ↗
Robert W. Baird & Co. Inc. BrokerCheck CRD 8158 ↗		EDGAR ↗
Jan 16, 2024 D
ALEXANDRIA REAL ESTATE EQUITIES, INC.
File 021-502546
$0$0$2,929,000 (est.)
Held by Issuer for payments of deferred compensation obligations to participants.
None listed on this filingEDGAR ↗
Jan 16, 2024 D
ALEXANDRIA REAL ESTATE EQUITIES, INC.
File 021-502552
$0$0$1,280,000
Held by Issuer for payments of deferred compensation obligations to participants.
None listed on this filingEDGAR ↗
May 5, 2023 D
Applied Therapeutics, Inc.
File 021-481003
$2,100,000 (est.)$0$0SVB Securities LLC BrokerCheck CRD 39011 ↗
UBS Securities LLC BrokerCheck CRD 7654 ↗		EDGAR ↗
Jan 17, 2023 D
ALEXANDRIA REAL ESTATE EQUITIES, INC.
File 021-470920
$0$0$3,699,463 (est.)
Held by Issuer for payments of deferred compensation obligations to participants.
None listed on this filingEDGAR ↗
Jan 17, 2023 D
ALEXANDRIA REAL ESTATE EQUITIES, INC.
File 021-470925
$0$0$980,000
Held by Issuer for payments of deferred compensation obligations to participants.
None listed on this filingEDGAR ↗
Jul 26, 2022 D
AltPep Corp
File 021-453730
$0$0$0None listed on this filingEDGAR ↗
Jul 7, 2022 D
ARE-MA Region No. 107 REIT, LLC
File 021-451437
$6,250$0$0Charles Harrison BrokerCheck CRD 3071551 ↗
via H & L Equities, LLC (CRD 113794 ↗)

Lori Mayfield BrokerCheck CRD 4899271 ↗
via H & L Equities, LLC (CRD 113794 ↗)

Patrick Whelchel BrokerCheck CRD 5389090 ↗
via H & L Equities, LLC (CRD 113794 ↗)

Scott Harrison BrokerCheck CRD 4981070 ↗
via H & L Equities, LLC (CRD 113794 ↗)

Charles Mathes BrokerCheck CRD 5980160 ↗
via H & L Equities, LLC (CRD 113794 ↗)
EDGAR ↗
Jan 20, 2022 D
Equilibre BioPharmaceuticals Corp.
File 021-430166
$0$0$0None listed on this filingEDGAR ↗
Jan 18, 2022 D
ALEXANDRIA REAL ESTATE EQUITIES, INC.
File 021-429812
$0$0$745,000
Held by Issuer for payments of deferred compensation obligations to participants.
None listed on this filingEDGAR ↗
Jan 18, 2022 D
ALEXANDRIA REAL ESTATE EQUITIES, INC.
File 021-429813
$0$0$3,809,375 (est.)
Held by Issuer for payments of deferred compensation obligations to participants.
None listed on this filingEDGAR ↗
Dec 30, 2021 D
ARE-MA Region No. 102 REIT, LLC
File 021-427416
$6,250$0$0Charles Harrison BrokerCheck CRD 3071551 ↗
via H & L Equities, LLC (CRD 113794 ↗)

Lori Mayfield BrokerCheck CRD 4899271 ↗
via H & L Equities, LLC (CRD 113794 ↗)

Patrick Whelchel BrokerCheck CRD 5389090 ↗
via H & L Equities, LLC (CRD 113794 ↗)

Scott Harrison BrokerCheck CRD 4981070 ↗
via H & L Equities, LLC (CRD 113794 ↗)

Charles Mathes BrokerCheck CRD 5980160 ↗
via H & L Equities, LLC (CRD 113794 ↗)
EDGAR ↗
Feb 5, 2021 D
ARE-Winter Street REIT, LLC
File 021-388622
$6,250$0$0Charles Harrison BrokerCheck CRD 3071551 ↗
via H & L Equities, LLC (CRD 113794 ↗)

Lori Mayfield BrokerCheck CRD 4899271 ↗
via H & L Equities, LLC (CRD 113794 ↗)

Patrick Whelchel BrokerCheck CRD 5389090 ↗
via H & L Equities, LLC (CRD 113794 ↗)

Scott Harrison BrokerCheck CRD 4981070 ↗
via H & L Equities, LLC (CRD 113794 ↗)

Charles Mathes BrokerCheck CRD 5980160 ↗
via H & L Equities, LLC (CRD 113794 ↗)
EDGAR ↗
Jan 15, 2021 D
ALEXANDRIA REAL ESTATE EQUITIES, INC.
File 021-386552
$0$0$4,126,130 (est.)
Held by Issuer for payments of deferred compensation obligations to participants.
None listed on this filingEDGAR ↗
Jan 15, 2021 D
ALEXANDRIA REAL ESTATE EQUITIES, INC.
File 021-386568
$0$0$711,000
Held by Issuer for payments of deferred compensation obligations to participants.
None listed on this filingEDGAR ↗
Nov 12, 2020 D
Equilibre BioPharmaceuticals Corp.
File 021-380339
$0$0$0None listed on this filingEDGAR ↗
Jan 16, 2020 D
ALEXANDRIA REAL ESTATE EQUITIES, INC.
File 021-358189
$0$0$666,000
Held by Issuer for payments of deferred compensation obligations to participants.
None listed on this filingEDGAR ↗
Jan 15, 2020 D
ALEXANDRIA REAL ESTATE EQUITIES, INC.
File 021-358180
$0$0$2,049,549 (est.)
Held by Issuer for payments of deferred compensation obligations to participants.
None listed on this filingEDGAR ↗
Nov 21, 2019 D
Applied Therapeutics, Inc.
File 021-353945
$1,250,449 (est.)$0$0John Dexter Pearson BrokerCheck CRD 6093501 ↗
via Collage Partners, a division of CIM Securities LLC (CRD 120852 ↗)

N/A no CRD number reported
via Cowen and Company, LLC (CRD 7616 ↗)

N/A no CRD number reported
via UBS Securities LLC (CRD 7654 ↗)
EDGAR ↗
Jul 11, 2019 D/A
Proniras Corp
File 021-294038
$0$0$0None listed on this filingEDGAR ↗
Mar 29, 2019 D/A
Rodeo Therapeutics Corp
File 021-327473
$0$0$0None listed on this filingEDGAR ↗
Jan 15, 2019 D
ALEXANDRIA REAL ESTATE EQUITIES, INC.
File 021-330594
$0$0$576,000
Held by Issuer for payments of deferred compensation obligations to participants.
None listed on this filingEDGAR ↗
Jan 15, 2019 D
ALEXANDRIA REAL ESTATE EQUITIES, INC.
File 021-330627
$0$0$1,835,790 (est.)
Held by Issuer for payments of deferred compensation obligations to participants.
None listed on this filingEDGAR ↗
Nov 19, 2018 D
Applied Therapeutics, Inc.
File 021-326111
$521,713$0$0CIM Securities, LLC BrokerCheck CRD 120852 ↗EDGAR ↗
Aug 24, 2018 D/A
ApoGen Biotechnologies, Inc.
File 021-275911
$0$0$0None listed on this filingEDGAR ↗
Aug 17, 2018 D
Magnolia Neurosciences Corp
File 021-319505
$0$0$0None listed on this filingEDGAR ↗
Feb 20, 2018 D
Applied Therapeutics, Inc.
File 021-306032
$420,000 (est.)$0$0
None except for normal operation expenses
Brookline Capital Market BrokerCheck CRD 120852 ↗
via a division of CIM Securities, LLC (CRD 120852 ↗)
EDGAR ↗
Jan 22, 2018 D/A
Petra Pharma Corp
File 021-254662
$0$0$0None listed on this filingEDGAR ↗
Jan 16, 2018 D
ALEXANDRIA REAL ESTATE EQUITIES, INC.
File 021-303349
$0$0$2,217,469 (est.)
Held by Issuer for payments of deferred compensation obligations to participants.
None listed on this filingEDGAR ↗
Jan 16, 2018 D
ALEXANDRIA REAL ESTATE EQUITIES, INC.
File 021-303354
$0$0$356,000
Held by Issuer for payments of deferred compensation obligations to participants.
None listed on this filingEDGAR ↗
Aug 2, 2017 D
Rodeo Therapeutics Corp
File 021-291967
$0$0$0None listed on this filingEDGAR ↗
Jan 13, 2017 D
ALEXANDRIA REAL ESTATE EQUITIES, INC.
File 021-278442
$0$0$1,625,924 (est.)
Held by Issuer for payments of deferred compensation obligations to participants.
None listed on this filingEDGAR ↗
Jan 13, 2017 D
ALEXANDRIA REAL ESTATE EQUITIES, INC.
File 021-278452
$0$0$110,000
Held by Issuer for payments of deferred compensation obligations to participants.
None listed on this filingEDGAR ↗
Jan 4, 2017 D/A
Lodo Therapeutics Corp
File 021-254438
$0$0$0None listed on this filingEDGAR ↗
Jan 19, 2016 D
ALEXANDRIA REAL ESTATE EQUITIES, INC.
File 021-255443
$0$0$1,071,750 (est.)
Held by issuer for payments of deferred compensation obligations to participants.
None listed on this filingEDGAR ↗
Jan 19, 2016 D
ALEXANDRIA REAL ESTATE EQUITIES, INC.
File 021-255449
$0$0$0None listed on this filingEDGAR ↗
Jan 16, 2015 D
ALEXANDRIA REAL ESTATE EQUITIES, INC.
File 021-232422
$0$0$1,089,530
Held by issuer for payments of deferred compensation obligations to participants.
None listed on this filingEDGAR ↗
Jan 16, 2015 D
ALEXANDRIA REAL ESTATE EQUITIES, INC.
File 021-232423
$0$0$0None listed on this filingEDGAR ↗
Jan 16, 2015 D
ALEXANDRIA REAL ESTATE EQUITIES, INC.
File 021-232425
$0$0$2,571,784
Held by issuer for payments of deferred compensation obligations to participants.
None listed on this filingEDGAR ↗
Jan 16, 2015 D
ALEXANDRIA REAL ESTATE EQUITIES, INC.
File 021-232429
$0$0$0None listed on this filingEDGAR ↗
Jan 16, 2015 D
ALEXANDRIA REAL ESTATE EQUITIES, INC.
File 021-232432
$0$0$965,750 (est.)
Held by issuer for payments of deferred compensation obligations to participants.
None listed on this filingEDGAR ↗
Jan 16, 2015 D
ALEXANDRIA REAL ESTATE EQUITIES, INC.
File 021-232431
$0$0$0None listed on this filingEDGAR ↗
Jan 13, 2014 D
Nina Biotherapeutics, Inc.
File 021-209861
$0$0$0None listed on this filingEDGAR ↗
Jan 13, 2014 D
Pinta Biotherapeutics, Inc.
File 021-209862
$0$0$0None listed on this filingEDGAR ↗
Jan 13, 2014 D
Santa Maria Biotherapeutics, Inc.
File 021-209863
$0$0$0None listed on this filingEDGAR ↗
Dec 10, 2013 D
Nina Biotherapeutics, Inc.
File 021-207719
$0$0$0None listed on this filingEDGAR ↗
Dec 10, 2013 D
Pinta Biotherapeutics, Inc.
File 021-207720
$0$0$0None listed on this filingEDGAR ↗
Dec 10, 2013 D
Santa Maria Biotherapeutics, Inc.
File 021-207721
$0$0$0None listed on this filingEDGAR ↗
Sep 11, 2013 D
INTRA CELLULAR THERAPIES INC
File 021-202684
$2,905,000 (est.)$0$0Leerink Swann LLC BrokerCheck CRD 39011 ↗
National Securities Corporation BrokerCheck CRD 7569 ↗
Livingston Securities, LLC BrokerCheck CRD 147364 ↗		EDGAR ↗
Jun 25, 2013 D/A
INTRA CELLULAR THERAPIES INC
File 021-194277
$0$0$0None listed on this filingEDGAR ↗
Jun 25, 2013 D
INTRA CELLULAR THERAPIES INC
File 021-198529
$0$0$0None listed on this filingEDGAR ↗
Jan 13, 2012 D
ALEXANDRIA REAL ESTATE EQUITIES, INC.
File 021-171830
$0$0$200,000 (est.)
Held by issuer for payments of deferred compensation obligations to participants.
None listed on this filingEDGAR ↗
Jan 13, 2012 D
ALEXANDRIA REAL ESTATE EQUITIES, INC.
File 021-171883
$0$0$0
Held by issuer for payments of deferred compensation obligations to participants.
None listed on this filingEDGAR ↗
Jan 10, 2011 D
ALEXANDRIA REAL ESTATE EQUITIES, INC.
File 021-153362
$0$0$278,500 (est.)
Held by issuer for payments of deferred compensation obligations to participants.
None listed on this filingEDGAR ↗
Jan 10, 2011 D
ALEXANDRIA REAL ESTATE EQUITIES, INC.
File 021-153363
$0$0$0
Held by issuer for payments of deferred compensation obligations to participants.
None listed on this filingEDGAR ↗
Mar 8, 2010 D
INTRA CELLULAR THERAPIES INC
File 021-45025
$0$0$0None listed on this filingEDGAR ↗
Jan 19, 2010 D
ALEXANDRIA REAL ESTATE EQUITIES, INC.
File 021-41415
$0$0$0
Held by issuer for payments of deferred compensation obligations to participants.
None listed on this filingEDGAR ↗
How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Counted across every filing this person is listed on (latest filing per offering, per issuer).

Deals 18

Every issuer that named Joel S. Marcus on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.

AR
REITS and Finance · group: Are

ALEXANDRIA REAL ESTATE EQUITIES, INC.

Pasadena, CA · Aug 11, 2009 → Jan 15, 2026 · 54 filings
  • Jan 15, 2026 · D · $1,000,000 sold of $1,170,000 · 5 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jan 15, 2026 · D · $53,448 sold of $4,660,978 · 14 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jan 15, 2025 · D · $1,000,000 sold of $1,280,000 · 5 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jan 15, 2025 · D · $66,141 sold of $5,543,510 · 18 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jan 16, 2024 · D · $1,000,000 sold of $1,280,000 · 5 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jan 16, 2024 · D · $48,152 sold of $5,082,207 · 16 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jan 17, 2023 · D · $700,000 sold of $980,000 · 4 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jan 17, 2023 · D · $34,256 sold of $5,495,713 · 18 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jan 18, 2022 · D · $48,917 sold of $5,751,688 · 15 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jan 18, 2022 · D · $465,000 sold of $745,000 · 3 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jan 15, 2021 · D · $465,000 sold of $711,000 · 3 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jan 15, 2021 · D · $43,692 sold of $5,617,595 · 13 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jan 16, 2020 · D · $420,000 sold of $666,000 · 3 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jan 15, 2020 · D · $43,931 sold of $4,617,554 · 14 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jan 15, 2019 · D · $39,228 sold of $4,331,728 · 17 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jan 15, 2019 · D · $330,000 sold of $576,000 · 3 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jan 16, 2018 · D · $220,000 sold of $356,000 · 2 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jan 16, 2018 · D · $41,738 sold of $4,113,287 · 22 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jan 13, 2017 · D · $110,000 sold of $110,000 · 1 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jan 13, 2017 · D · $40,345 sold of $3,563,233 · 20 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jan 19, 2016 · D · $0 sold of Indefinite · 0 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jan 19, 2016 · D · $28,254 sold of $2,133,161 · 16 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jan 16, 2015 · D · $0 sold of Indefinite · 0 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jan 16, 2015 · D · $17,337 sold of $1,075,500 · 4 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jan 16, 2015 · D · $0 sold of Indefinite · 0 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jan 16, 2015 · D · $2,701,298 sold of $2,701,298 · 7 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jan 16, 2015 · D · $0 sold of Indefinite · 0 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jan 16, 2015 · D · $1,089,530 sold of $1,089,530 · 3 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jan 13, 2012 · D · $0 sold of Indefinite · 0 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jan 13, 2012 · D · $0 sold of $580,000 · 3 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jan 10, 2011 · D · $0 sold of Indefinite · 0 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jan 10, 2011 · D · $0 sold of $576,000 · 3 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jan 19, 2010 · D · $0 sold of Indefinite · 0 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jan 19, 2010 · D · $0 sold of $403,250 · 4 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Aug 12, 2009 · D · $1,414,150 sold of $1,414,150 · 5 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Aug 12, 2009 · D · $276,611 sold of $276,611 · 6 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Aug 12, 2009 · D · $78,750 sold of $78,750 · 1 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Aug 12, 2009 · D · $0 sold of Indefinite · 0 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Aug 12, 2009 · D · $998,488 sold of $998,488 · 4 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Aug 12, 2009 · D · $387,232 sold of $387,232 · 5 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Aug 12, 2009 · D · $372,375 sold of $372,375 · 6 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Aug 12, 2009 · D · $262,435 sold of $262,435 · 6 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Aug 12, 2009 · D · $0 sold of $40,000 · 1 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Aug 12, 2009 · D · $1,009,300 sold of $1,009,300 · 5 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Aug 11, 2009 · D · $285,656 sold of $285,656 · 7 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Aug 11, 2009 · D · $325,873 sold of $325,873 · 6 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Aug 11, 2009 · D · $517,009 sold of $517,009 · 6 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Aug 11, 2009 · D · $632,948 sold of $632,948 · 6 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Aug 11, 2009 · D · $250,505 sold of $250,505 · 1 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Aug 11, 2009 · D · $293,352 sold of $293,352 · 1 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Aug 11, 2009 · D · $215,480 sold of $215,480 · 2 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Aug 11, 2009 · D · $127,793 sold of $127,793 · 1 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Aug 11, 2009 · D · $94,000 sold of $94,000 · 1 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Aug 11, 2009 · D · $115,780 sold of $115,780 · 2 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗

Raised $2.7M from 22 investors (100% of the $1.17M target) as of the latest filing. Joel is listed as executive officer, director on 54 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: REITS and Finance / 506(b) (3,490 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

TH
Biotechnology

TRex Holdings Inc.

South San Francisco, CA · Nov 26, 2024
  • Nov 26, 2024 · D · $42,279,369 sold of $85,000,000 · 13 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $42.3M from 13 investors (50% of the $85M target) as of the latest filing. Joel is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AT
Biotechnology

Applied Therapeutics, Inc.

New York, NY · Feb 20, 2018 → Mar 13, 2024 · 5 filings
  • Mar 13, 2024 · D · $99,997,998 sold of $99,997,998 · 31 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 5, 2023 · D · $30,000,002 sold of $30,000,002 · 19 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 21, 2019 · D · $20,014,988 sold of $20,014,988 · 12 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 19, 2018 · D · $27,158,092 sold of $56,584,093 · 37 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 20, 2018 · D · $6,000,000 sold of $6,000,000 · 23 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $100M from 37 investors (100% of the $100M target) as of the latest filing. Joel is listed as director on 5 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AC
Biotechnology

AltPep Corp

Seattle, WA · Jul 26, 2022
  • Jul 26, 2022 · D · $44,399,972 sold of $74,999,996 · 12 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $44.4M from 26 investors (59% of the $75M target) as of the latest filing. Joel is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AM
REITS and Finance · group: Are

ARE-MA Region No. 107 REIT, LLC

Pasadena, CA · Jul 7, 2022
  • Jul 7, 2022 · D · $125,000 sold of $125,000 · 125 investors · min. $1,000 · role: Executive Officer EDGAR ↗

Raised $125K from 125 investors (100% of the $125K target) as of the latest filing. Joel is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: REITS and Finance / 506(b) (3,490 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

EB
Pharmaceuticals

Equilibre BioPharmaceuticals Corp.

New York, NY · Nov 12, 2020 → Jan 20, 2022 · 2 filings
  • Jan 20, 2022 · D · $15,902,341 sold of $25,000,000 · 14 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 12, 2020 · D · $25,799,973 sold of $35,799,973 · 14 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $25.8M from 14 investors (100% of the $25M target) as of the latest filing. Joel is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AM
REITS and Finance · group: Are

ARE-MA Region No. 102 REIT, LLC

Pasadena, CA · Dec 30, 2021
  • Dec 30, 2021 · D · $125,000 sold of $125,000 · 125 investors · min. $1,000 · role: Executive Officer, Director EDGAR ↗

Raised $125K from 125 investors (100% of the $125K target) as of the latest filing. Joel is listed as executive officer, director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: REITS and Finance / 506(b) (3,490 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AW
REITS and Finance · group: Are

ARE-Winter Street REIT, LLC

Pasadena, CA · Feb 5, 2021
  • Feb 5, 2021 · D · $125,000 sold of $125,000 · 125 investors · min. $1,000 · role: Executive Officer, Director EDGAR ↗

Raised $125K from 125 investors (100% of the $125K target) as of the latest filing. Joel is listed as executive officer, director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: REITS and Finance / 506(b) (3,490 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

PC
Biotechnology

Proniras Corp

Seattle, WA · Sep 5, 2017 → Jul 11, 2019 · 2 filings
  • Jul 11, 2019 · D/A · $4,300,000 sold of $4,300,000 · 7 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 5, 2017 · D · $2,800,000 sold of $2,800,000 · 7 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $6.93M from 10 investors (100% of the $4.3M target) as of the latest filing. Joel is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

RT
Biotechnology

Rodeo Therapeutics Corp

Seattle, WA · Aug 2, 2017 → Mar 29, 2019 · 3 filings
  • Mar 29, 2019 · D/A · $7,949,999 sold of $7,949,999 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 10, 2018 · D · $3,685,714 sold of $4,571,475 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 2, 2017 · D · $5,354,000 sold of $5,900,000 · 8 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $8.95M from 9 investors (100% of the $7.95M target) as of the latest filing. Joel is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AB
Biotechnology

ApoGen Biotechnologies, Inc.

Seattle, WA · Dec 8, 2016 → Aug 24, 2018 · 2 filings
  • Aug 24, 2018 · D/A · $7,565,892 sold of $7,565,892 · 24 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 8, 2016 · D · $3,815,892 sold of $7,315,892 · 23 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $7.57M from 24 investors (100% of the $7.57M target) as of the latest filing. Joel is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

MN
Biotechnology

Magnolia Neurosciences Corp

New York, NY · Aug 17, 2018
  • Aug 17, 2018 · D · $8,000,000 sold of $13,090,909 · 11 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $18.4M from 11 investors (100% of the $13.1M target) as of the latest filing. Joel is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

PP
Biotechnology

Petra Pharma Corp

New York, NY · Jan 6, 2016 → Jan 22, 2018 · 3 filings
  • Jan 22, 2018 · D/A · $31,204,516 sold of $48,250,000 · 13 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 4, 2017 · D/A · $21,204,511 sold of $48,250,000 · 11 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 6, 2016 · D · $9,992,200 sold of $10,410,478 · 12 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $31.2M from 13 investors (65% of the $48.3M target) as of the latest filing. Joel is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

LT
Biotechnology

Lodo Therapeutics Corp

New York, NY · Jan 4, 2016 → Jan 4, 2017 · 2 filings
  • Jan 4, 2017 · D/A · $19,867,600 sold of $19,867,600 · 13 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 4, 2016 · D · $3,517,600 sold of $3,658,304 · 13 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $19.9M from 13 investors (100% of the $19.9M target) as of the latest filing. Joel is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

SM
Biotechnology · group: Santa

Santa Maria Biotherapeutics, Inc.

Brisbane, CA · Dec 10, 2013 → Jan 13, 2014 · 2 filings
  • Jan 13, 2014 · D · $6,311,156 sold of $6,311,156 · 10 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 10, 2013 · D · $17,998,555 sold of $17,998,555 · 12 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $18M from 12 investors (100% of the $6.31M target) as of the latest filing. Joel is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

PB
Biotechnology · group: Santa

Pinta Biotherapeutics, Inc.

Brisbane, CA · Dec 10, 2013 → Jan 13, 2014 · 2 filings
  • Jan 13, 2014 · D · $6,311,156 sold of $6,311,156 · 10 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 10, 2013 · D · $17,998,555 sold of $17,998,555 · 12 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $18M from 12 investors (100% of the $6.31M target) as of the latest filing. Joel is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

NB
Biotechnology · group: Santa

Nina Biotherapeutics, Inc.

Brisbane, CA · Dec 10, 2013 → Jan 13, 2014 · 2 filings
  • Jan 13, 2014 · D · $877,688 sold of $877,688 · 10 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 10, 2013 · D · $2,503,048 sold of $2,503,048 · 12 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $2.5M from 12 investors (100% of the $878K target) as of the latest filing. Joel is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

IC
Biotechnology · group: Intra Cellular Therapies

INTRA CELLULAR THERAPIES INC

New York, NY · Mar 8, 2010 → Sep 11, 2013 · 6 filings
  • Sep 11, 2013 · D · $60,000,000 sold of $60,000,000 · 185 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 25, 2013 · D · $241,633 sold of $241,633 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 25, 2013 · D/A · $15,289,893 sold of $15,400,000 · 12 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 17, 2013 · D/A · $15,289,893 sold of $15,400,000 · 12 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 1, 2013 · D · $15,289,893 sold of $15,400,000 · 12 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 8, 2010 · D · $5,335,780 sold of $8,000,000 · 10 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $60M from 185 investors (100% of the $60M target) as of the latest filing. Joel is listed as director on 6 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

Other pages with the same name (2)

Separate person records under the same name, not combined with this page. Each line says whether it shares an issuer with this record.

  • Joel Marcus — MA, 3 issuers, Feb 22, 2016 → Jul 23, 2019 · no shared issuer
  • Joel Marcus — NC, 2 issuers, Mar 22, 2017 → May 15, 2020 · no shared issuer

People around Joel 40

Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.

RK
No photo found yet (own website and image search run after this page is viewed)
Person

Richard H. Klein

Director · 54 shared filings (1 issuer)

Listed on the same filings as Joel S. Marcus. Their page shows their other deals.

DS
No photo found yet (own website and image search run after this page is viewed)
Person

Dean A. Shigenaga

Executive Officer, Director · 51 shared filings (4 issuers)

Listed on the same filings as Joel S. Marcus. Their page shows their other deals.

JA
No photo found yet (own website and image search run after this page is viewed)
Person

John L. Atkins, III

Director · 44 shared filings (1 issuer)

Listed on the same filings as Joel S. Marcus. Their page shows their other deals.

JR
No photo found yet (own website and image search run after this page is viewed)
Person

James Richardson

Director · 44 shared filings (1 issuer)

Listed on the same filings as Joel S. Marcus. Their page shows their other deals.

RJ
No photo found yet (own website and image search run after this page is viewed)
Person

Richard B. Jennings

Director · 34 shared filings (1 issuer)

Listed on the same filings as Joel S. Marcus. Their page shows their other deals.

PM
No photo found yet (own website and image search run after this page is viewed)
Person

Peter M. Moglia

Executive Officer · 31 shared filings (4 issuers)

Listed on the same filings as Joel S. Marcus. Their page shows their other deals.

DR
No photo found yet (own website and image search run after this page is viewed)
Person

Daniel Ryan

Executive Officer · 29 shared filings (4 issuers)

Listed on the same filings as Joel S. Marcus. Their page shows their other deals.

MD
No photo found yet (own website and image search run after this page is viewed)
Person

Maria C. Freire, Ph.D.

Director · 28 shared filings (1 issuer)

Listed on the same filings as Joel S. Marcus. Their page shows their other deals.

SH
No photo found yet (own website and image search run after this page is viewed)
Person

Steven R. Hash

Director · 28 shared filings (1 issuer)

Listed on the same filings as Joel S. Marcus. Their page shows their other deals.

MS
No photo found yet (own website and image search run after this page is viewed)
Person

Martin A. Simonetti

Director · 26 shared filings (1 issuer)

Listed on the same filings as Joel S. Marcus. Their page shows their other deals.

AW
No photo found yet (own website and image search run after this page is viewed)
Person

Alan G. Walton

Director · 26 shared filings (1 issuer)

Listed on the same filings as Joel S. Marcus. Their page shows their other deals.

SR
No photo found yet (own website and image search run after this page is viewed)
Person

Stephen A. Richardson

Executive Officer · 25 shared filings (4 issuers)

Listed on the same filings as Joel S. Marcus. Their page shows their other deals.

JC
No photo found yet (own website and image search run after this page is viewed)
Person

James P. Cain

Director · 22 shared filings (1 issuer)

Listed on the same filings as Joel S. Marcus. Their page shows their other deals.

LD
No photo found yet (own website and image search run after this page is viewed)
Person

Lawrence Diamond

Executive Officer · 19 shared filings (4 issuers)

Listed on the same filings as Joel S. Marcus. Their page shows their other deals.

MW
No photo found yet (own website and image search run after this page is viewed)
Person

Michael A. Woronoff

Director · 18 shared filings (1 issuer)

Listed on the same filings as Joel S. Marcus. Their page shows their other deals.

MB
No photo found yet (own website and image search run after this page is viewed)
Person

Marc E. Binda

Executive Officer · 17 shared filings (4 issuers)

Listed on the same filings as Joel S. Marcus. Their page shows their other deals.

TA
No photo found yet (own website and image search run after this page is viewed)
Person

Thomas J. Andrews

Executive Officer · 16 shared filings (1 issuer)

Listed on the same filings as Joel S. Marcus. Their page shows their other deals.

JH
No photo found yet (own website and image search run after this page is viewed)
Person

Joseph Hakman

Executive Officer · 16 shared filings (3 issuers)

Listed on the same filings as Joel S. Marcus. Their page shows their other deals.

VC
No photo found yet (own website and image search run after this page is viewed)
Person

Vincent R. Ciruzzi

Executive Officer · 15 shared filings (4 issuers)

Listed on the same filings as Joel S. Marcus. Their page shows their other deals.

GD
No photo found yet (own website and image search run after this page is viewed)
Person

Gary D. Dean

Executive Officer · 15 shared filings (4 issuers)

Listed on the same filings as Joel S. Marcus. Their page shows their other deals.

JC
No photo found yet (own website and image search run after this page is viewed)
Person

Jackie B. Clem

Executive Officer, Director · 15 shared filings (4 issuers)

Listed on the same filings as Joel S. Marcus. Their page shows their other deals.

HK
No photo found yet (own website and image search run after this page is viewed)
Person

Hunter L. Kass

Executive Officer, Director · 15 shared filings (4 issuers)

Listed on the same filings as Joel S. Marcus. Their page shows their other deals.

AG
No photo found yet (own website and image search run after this page is viewed)
Person

Andres R. Gavinet

Executive Officer · 15 shared filings (4 issuers)

Listed on the same filings as Joel S. Marcus. Their page shows their other deals.

TL
No photo found yet (own website and image search run after this page is viewed)
Person

Thong Le

Executive Officer, Director, Promoter · 13 shared filings (6 issuers) · also on 8 other issuers

Thong Le is on 14 issuers in total — a repeat sponsor. Their page lists every one.

SG
No photo found yet (own website and image search run after this page is viewed)
Person

Steve Gillis

Director, Executive Officer, Promoter · 13 shared filings (6 issuers) · also on 9 other issuers

Steve Gillis is on 15 issuers in total — a repeat sponsor. Their page lists every one.

JC
No photo found yet (own website and image search run after this page is viewed)
Person

John H. Cunningham

Executive Officer · 13 shared filings (4 issuers)

Listed on the same filings as Joel S. Marcus. Their page shows their other deals.

AX
No photo found yet (own website and image search run after this page is viewed)
Person

Asish Xavier

Director · 11 shared filings (6 issuers) · also on 16 other issuers

Asish Xavier is on 22 issuers in total — a repeat sponsor. Their page lists every one.

DS
No photo found yet (own website and image search run after this page is viewed)
Person

David Schubert

Executive Officer, Promoter · 11 shared filings (6 issuers) · also on 3 other issuers

David Schubert is on 9 issuers in total — a repeat sponsor. Their page lists every one.

LR
No photo found yet (own website and image search run after this page is viewed)
Person

Lindsay Rayle

Executive Officer, Promoter · 9 shared filings (5 issuers) · also on 4 other issuers

Lindsay Rayle is on 9 issuers in total — a repeat sponsor. Their page lists every one.

MA
No photo found yet (own website and image search run after this page is viewed)
Person

Madeleine T. Alsbrook

Executive Officer · 8 shared filings (1 issuer)

Listed on the same filings as Joel S. Marcus. Their page shows their other deals.

OL
No photo found yet (own website and image search run after this page is viewed)
Person

Orraparn C. Lee

Executive Officer · 8 shared filings (1 issuer)

Listed on the same filings as Joel S. Marcus. Their page shows their other deals.

KC
No photo found yet (own website and image search run after this page is viewed)
Person

Kristina A. Fukuzaki-Carlson

Executive Officer · 8 shared filings (1 issuer)

Listed on the same filings as Joel S. Marcus. Their page shows their other deals.

CG
No photo found yet (own website and image search run after this page is viewed)
Person

Carol Gallagher

Director · 7 shared filings (4 issuers) · also on 11 other issuers

Carol Gallagher is on 15 issuers in total — a repeat sponsor. Their page lists every one.

TN
No photo found yet (own website and image search run after this page is viewed)
Person

Terezia C. Nemeth

Executive Officer · 7 shared filings (3 issuers)

Listed on the same filings as Joel S. Marcus. Their page shows their other deals.

BS
No photo found yet (own website and image search run after this page is viewed)
Person

Beth Seidenberg

Director · 6 shared filings (3 issuers) · also on 26 other issuers

Beth Seidenberg is on 29 issuers in total — a repeat sponsor. Their page lists every one.

JC
No photo found yet (own website and image search run after this page is viewed)
Person

John Hart Cole

Executive Officer · 6 shared filings (1 issuer)

Listed on the same filings as Joel S. Marcus. Their page shows their other deals.

EW
No photo found yet (own website and image search run after this page is viewed)
Person

Eckard Weber

Director · 6 shared filings (3 issuers) · also on 8 other issuers

Eckard Weber is on 11 issuers in total — a repeat sponsor. Their page lists every one.

JM
No photo found yet (own website and image search run after this page is viewed)
Person

John F. McGrath

Executive Officer · 6 shared filings (3 issuers) · also on 2 other issuers

John F. McGrath is on 5 issuers in total — a repeat sponsor. Their page lists every one.

LH
No photo found yet (own website and image search run after this page is viewed)
Person

Lawrence J. Hineline

Executive Officer · 6 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Joel S. Marcus. Their page shows their other deals.

RL
No photo found yet (own website and image search run after this page is viewed)
Person

Richard Lerner

Director · 6 shared filings (1 issuer)

Listed on the same filings as Joel S. Marcus. Their page shows their other deals.

The team behind the deals

A
Sponsor group

Are

6 issuers · 59 filings · $1.62M reported sold · 2009–2026

One team, 6 deal companies. Joel S. Marcus is listed on 4 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Joel S. Marcus.

S
Sponsor group

Santa

3 issuers · 6 filings · $13.5M reported sold · 2013–2014

One team, 3 deal companies. Joel S. Marcus is listed on 3 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Joel S. Marcus.

IC
Sponsor group

Intra Cellular Therapies

2 issuers · 7 filings · $130.3M reported sold · 2010–2013

One team, 2 deal companies. Joel S. Marcus is listed on 1 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Joel S. Marcus.

Same business address

29 other issuers file from the same address

A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.

Registrations and other filings

Adviser registration (Form ADV)

None of the 18 issuers this person is listed on appears in Form ADV (searched 24,962 advisers as of Oct 2, 2026). A person is never an adviser firm; Form ADV is checked for the issuers and the management companies they are listed with.

Other offering types (Regulation A and Regulation Crowdfunding)

Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.

Property records none — individuals are not matched

Property records are matched to companies only, never to individuals, so none are matched to Joel S. Marcus by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 18 issuers this person is listed on — nothing matched.

Public profiles and social

Websites and social links of the issuers Joel S. Marcus is listed on: none on file. No website or social profile named in AltPep Corp's SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #149,250 of 374,652 in line (564 issuers searched so far). One-tap searches: Look further ↓

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (Seattle, WA). Each opens in a new tab; what you find there is not verified by PartnerFacts.

Social and web

LinkedIn people search ↗Instagram ↗X (Twitter) ↗Facebook ↗YouTube ↗Google ↗Google Images ↗Google News ↗Meta Ad Library ↗

Courts

CourtListener / RECAP (federal) ↗PACER case locator (federal, login) ↗California — find the county court ↗Los Angeles Superior Court case search ↗New York WebCivil Supreme ↗Washington Courts case search (dw.courts.wa.gov) ↗

Securities regulators

SEC EDGAR full-text search ↗SEC action look-up ↗FINRA BrokerCheck ↗SEC IAPD adviser search ↗

Business registries

California Secretary of State business search ↗New York Secretary of State business search ↗Washington Secretary of State business search ↗OpenCorporates ↗

Change history

No corrections have been requested for this page.

Every fact links to its public-record source. Plain-English notes next to a fact are our reading of that fact, not a rating. Request a correction · Facts policy

Request a correction

Free. Logged with status: received → under review → fixed / confirmed with source.

Add a response

If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.

Monitor this person

Members get an email when Joel S. Marcus appears on a new Form D, or when a court case or SEC action is matched to them. See plans →